Advanced search
1 file | 847.23 KB Add to list

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Author
Organization
Abstract
More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard chemotherapy might improve their outcome. After establishing a safe lenalidomide, dose elderly patients with AML were randomly assigned in this randomized Phase 2 study (n = 222) to receive standard chemotherapy ("3 + 7") with or without lenalidomide at a dose of 20 mg/day 1-21. In the second cycle, patients received cytarabine 1000 mg/m(2) twice daily on days 1-6 with or without lenalidomide (20 mg/day 1-21). The CR/CRi rates in the two arms were not different (69 vs. 66%). Event-free survival (EFS) at 36 months was 19% for the standard arm versus 21% for the lenalidomide arm and overall survival (OS) 35% vs. 30%, respectively. The frequencies and grade of adverse events were not significantly different between the treatment arms. Cardiovascular toxicities were rare and equally distributed between the arms. The results of the present study show that the addition of lenalidomide to standard remission induction chemotherapy does not improve the therapeutic outcome of older AML patients. This trial is registered as number NTR2294 in The NederlandsTrial Register (www.trialregister.nl).
Keywords
ACUTE MYELOID-LEUKEMIA, HIGH-DOSE LENALIDOMIDE, THERAPY, ADULTS

Downloads

  • s41375-020-0725-0.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 847.23 KB

Citation

Please use this url to cite or link to this publication:

MLA
Ossenkoppele, G. J., et al. “Lenalidomide Added to Standard Intensive Treatment for Older Patients with AML and High-Risk MDS.” LEUKEMIA, Nature Publishing Group, 2020, doi:10.1038/s41375-020-0725-0.
APA
Ossenkoppele, G. J., Breems, D. A., Stuessi, G., Van Norden, Y., Bargetzi, M., Biemond, B. J., … Van Marwijk Kooy, M. (2020). Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. LEUKEMIA. https://doi.org/10.1038/s41375-020-0725-0
Chicago author-date
Ossenkoppele, G. J., D. A. Breems, G. Stuessi, Y. Van Norden, M. Bargetzi, B. J. Biemond, P. A von dem Borne, et al. 2020. “Lenalidomide Added to Standard Intensive Treatment for Older Patients with AML and High-Risk MDS.” LEUKEMIA. https://doi.org/10.1038/s41375-020-0725-0.
Chicago author-date (all authors)
Ossenkoppele, G. J., D. A. Breems, G. Stuessi, Y. Van Norden, M. Bargetzi, B. J. Biemond, P. A von dem Borne, Y. Chalandon, J. Cloos, D. Deeren, M. Fehr, B. Gjertsen, C. Graux, G. Huls, J. J. J. W. Janssen, A. Jaspers, M. Jongen-Lavrencic, E. De Jongh, S. K. Klein, M. Van der Klift, M. Van Marwijk Kooy, J. Maertens, L. Micheaux, M. W. M. Van der Poel, A. Van Rhenen, L. Tick, P. Valk, M. C. Vekemans, W. J. F. M. Van der Velden, O. De Weerdt, T. Pabst, M. Manz, B. Lowenberg, D. A. Breems, Havelange Havelange, M-C Vekemans, Ine Moors, F. Van Obberg, J. A. Maertens, B. Hodossy, S. Vansteenweghen, L. Lammertijn, D. Deeren, C. Graux, A. Sonet, A. Triffet, B. T. Gjertsen, M. Bargetzi, J. Passweg, D. Heim, San Giovanni, Georg Stuessi, T. Pabst, D. Betticher, Y. Chalandon, O. Spertini, M. Gregor, U. Hess, M. Fehr, M. G. Manz, S. K. Klein, B. J. Biemond, G. J. Ossenkoppele, A. Van de Loosdrecht, J. J. W. M. Janssen, J. W. J. Van Esser, M. Van der Klift, R. E. Brouwer, D. Van Lammeren-Venema, M. D. Levin, L. W. Tick, M. C. J. C. Legdeur, G. Huls, E. Vellenga, M. Hoogendoorn, J. H. Veelken, P. A. Von dem Borne, H. C. Schouten, O. De Weerdt, W. J. F. M. Van der Velden, J. Cornelissen, M. Jongen-Lavrencic, B. Wouters, H. G. M. Raaijmakers, B. Lowenberg, J. Kuball, A. Van Rhenen, and M. Van Marwijk Kooy. 2020. “Lenalidomide Added to Standard Intensive Treatment for Older Patients with AML and High-Risk MDS.” LEUKEMIA. doi:10.1038/s41375-020-0725-0.
Vancouver
1.
Ossenkoppele GJ, Breems DA, Stuessi G, Van Norden Y, Bargetzi M, Biemond BJ, et al. Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. LEUKEMIA. 2020;
IEEE
[1]
G. J. Ossenkoppele et al., “Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS,” LEUKEMIA, 2020.
@article{8668525,
  abstract     = {More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard chemotherapy might improve their outcome. After establishing a safe lenalidomide, dose elderly patients with AML were randomly assigned in this randomized Phase 2 study (n = 222) to receive standard chemotherapy ("3 + 7") with or without lenalidomide at a dose of 20 mg/day 1-21. In the second cycle, patients received cytarabine 1000 mg/m(2) twice daily on days 1-6 with or without lenalidomide (20 mg/day 1-21). The CR/CRi rates in the two arms were not different (69 vs. 66%). Event-free survival (EFS) at 36 months was 19% for the standard arm versus 21% for the lenalidomide arm and overall survival (OS) 35% vs. 30%, respectively. The frequencies and grade of adverse events were not significantly different between the treatment arms. Cardiovascular toxicities were rare and equally distributed between the arms. The results of the present study show that the addition of lenalidomide to standard remission induction chemotherapy does not improve the therapeutic outcome of older AML patients. This trial is registered as number NTR2294 in The NederlandsTrial Register (www.trialregister.nl).},
  author       = {Ossenkoppele, G. J. and Breems, D. A. and Stuessi, G. and Van Norden, Y. and Bargetzi, M. and Biemond, B. J. and A von dem Borne, P. and Chalandon, Y. and Cloos, J. and Deeren, D. and Fehr, M. and Gjertsen, B. and Graux, C. and Huls, G. and Janssen, J. J. J. W. and Jaspers, A. and Jongen-Lavrencic, M. and De Jongh, E. and Klein, S. K. and Van der Klift, M. and Van Marwijk Kooy, M. and Maertens, J. and Micheaux, L. and Van der Poel, M. W. M. and Van Rhenen, A. and Tick, L. and Valk, P. and Vekemans, M. C. and Van der Velden, W. J. F. M. and De Weerdt, O. and Pabst, T. and Manz, M. and Lowenberg, B. and Breems, D. A. and Havelange, Havelange and Vekemans, M-C and Moors, Ine and Van Obberg, F. and Maertens, J. A. and Hodossy, B. and Vansteenweghen, S. and Lammertijn, L. and Deeren, D. and Graux, C. and Sonet, A. and Triffet, A. and Gjertsen, B. T. and Bargetzi, M. and Passweg, J. and Heim, D. and Giovanni, San and Stuessi, Georg and Pabst, T. and Betticher, D. and Chalandon, Y. and Spertini, O. and Gregor, M. and Hess, U. and Fehr, M. and Manz, M. G. and Klein, S. K. and Biemond, B. J. and Ossenkoppele, G. J. and Van de Loosdrecht, A. and Janssen, J. J. W. M. and Van Esser, J. W. J. and Van der Klift, M. and Brouwer, R. E. and Van Lammeren-Venema, D. and Levin, M. D. and Tick, L. W. and Legdeur, M. C. J. C. and Huls, G. and Vellenga, E. and Hoogendoorn, M. and Veelken, J. H. and Von dem Borne, P. A. and Schouten, H. C. and De Weerdt, O. and Van der Velden, W. J. F. M. and Cornelissen, J. and Jongen-Lavrencic, M. and Wouters, B. and Raaijmakers, H. G. M. and Lowenberg, B. and Kuball, J. and Van Rhenen, A. and Van Marwijk Kooy, M.},
  issn         = {0887-6924},
  journal      = {LEUKEMIA},
  keywords     = {ACUTE MYELOID-LEUKEMIA,HIGH-DOSE LENALIDOMIDE,THERAPY,ADULTS},
  language     = {eng},
  pages        = {9},
  publisher    = {Nature Publishing Group},
  title        = {Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS},
  url          = {http://dx.doi.org/10.1038/s41375-020-0725-0},
  year         = {2020},
}

Altmetric
View in Altmetric
Web of Science
Times cited: